The Medicines Company (MDCO) Receives Consensus Rating of “Buy” from Brokerages

The Medicines Company (NASDAQ:MDCO) has earned a consensus recommendation of “Buy” from the fourteen research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $56.86.

Several equities research analysts have recently issued reports on MDCO shares. CIBC set a $50.00 target price on The Medicines Company in a report on Tuesday, May 23rd. Jefferies Group LLC reaffirmed a “buy” rating and issued a $62.00 target price on shares of The Medicines Company in a report on Wednesday, April 12th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of The Medicines Company in a report on Monday, March 20th. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of The Medicines Company in a report on Saturday, March 18th. Finally, Royal Bank Of Canada reaffirmed a “buy” rating on shares of The Medicines Company in a report on Wednesday, March 1st.

Several hedge funds and other institutional investors have recently made changes to their positions in MDCO. Renaissance Technologies LLC raised its position in shares of The Medicines Company by 5,034.6% in the fourth quarter. Renaissance Technologies LLC now owns 415,900 shares of the company’s stock valued at $14,116,000 after buying an additional 407,800 shares during the period. FMR LLC raised its stake in shares of The Medicines Company by 0.8% in the first quarter. FMR LLC now owns 10,707,056 shares of the company’s stock worth $523,575,000 after buying an additional 87,958 shares during the last quarter. Panagora Asset Management Inc. raised its stake in shares of The Medicines Company by 26.9% in the third quarter. Panagora Asset Management Inc. now owns 482,458 shares of the company’s stock worth $18,208,000 after buying an additional 102,164 shares during the last quarter. HighVista Strategies LLC raised its stake in shares of The Medicines Company by 32.0% in the third quarter. HighVista Strategies LLC now owns 268,240 shares of the company’s stock worth $10,123,000 after buying an additional 65,040 shares during the last quarter. Finally, BlackRock Inc. raised its stake in shares of The Medicines Company by 11.5% in the third quarter. BlackRock Inc. now owns 8,195 shares of the company’s stock worth $309,000 after buying an additional 847 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/06/19/brokerages-set-the-medicines-company-mdco-price-target-at-58-00-updated-updated.html.

The Medicines Company (NASDAQ MDCO) opened at 37.09 on Monday. The company has a 50 day moving average price of $42.64 and a 200 day moving average price of $43.88. The firm’s market capitalization is $2.64 billion. The Medicines Company has a 12 month low of $30.80 and a 12 month high of $55.95.

The Medicines Company (NASDAQ:MDCO) last issued its earnings results on Wednesday, April 26th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.13) by $0.31. The Medicines Company had a negative return on equity of 19.09% and a negative net margin of 91.25%. The firm had revenue of $24.20 million during the quarter, compared to the consensus estimate of $37.76 million. During the same period last year, the firm posted ($1.03) earnings per share. The company’s revenue for the quarter was down 51.9% compared to the same quarter last year. Analysts anticipate that The Medicines Company will post ($5.97) earnings per share for the current fiscal year.

The Medicines Company Company Profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply